艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

交易中 07-26 12:38:35 EDT

68.63

+0.73

+1.08%

最高68.73	最低68.05	成交量30.53万
今开68.46	昨收67.90	日振幅1.00%
总市值68.90亿	流通市值67.60亿	总股本1.00亿
成交额2,086万	换手率0.31%	流通股本9,850万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":68.63,"timestamp":1722011892965,"preClose":67.9,"halted":0,"volume":305253,"delay":0,"floatShares":98501691,"shares":100397549,"eps":1.79149,"marketStatus":"交易中","marketStatusCode":2,"change":0.73,"latestTime":"07-26 12:38:35 EDT","open":68.46,"high":68.73,"low":68.05,"amount":20857400.244719997,"amplitude":0.010015,"askPrice":68.65,"askSize":11,"bidPrice":68.63,"bidSize":25,"shortable":3,"etf":0,"ttmEps":1.79149,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1722024000000},"adr":0,"listingDate":766296000000,"adjPreClose":67.9,"adrRate":0,"dividendRate":0.043144,"preHourTrading":{"tag":"盘前","latestPrice":68.25,"preClose":67.9,"latestTime":"08:24 EDT","volume":54,"amount":3680.599824,"timestamp":1721996667735},"postHourTrading":{"tag":"盘后","latestPrice":67.9,"preClose":67.9,"latestTime":"19:00 EDT","volume":15224,"amount":1033724.22,"timestamp":1721948407272},"volumeRatio":0.564873,"impliedVol":0.2092,"impliedVolPercentile":0.2103},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2454360429","title":"博安生物一款ADC新药获批临床 拟用于晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2454360429","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454360429?lang=zh_cn&edition=full","pubTime":"2024-07-26 14:28","pubTimestamp":1721975303,"startTime":"0","endTime":"0","summary":"7月25日，国家药监局药品审评中心官网公示，博安生物申报的1类新药注射用BA1302获批临床，拟开发治疗晚期实体瘤。黑色素转铁蛋白（CD228）是一种铁结合转铁蛋白同源物的膜结合糖蛋白，首次被报道为黑色素瘤相关抗原，在肿瘤迁移和增殖中发挥作用。该蛋白靶点在黑色素瘤、间皮瘤、结肠癌、乳腺癌、胰腺癌和非小细胞肺癌等多种肿瘤中高表达，并在正常组织中低表达，具有较高的肿瘤表达特异性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407263141077572.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407263141077572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK1161","06955","BK4080","BK4231"],"gpt_icon":0},{"id":"2454024718","title":"Nuvation Bio Inc.盘中异动 股价大涨5.26%报3.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454024718","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454024718?lang=zh_cn&edition=full","pubTime":"2024-07-26 00:34","pubTimestamp":1721925289,"startTime":"0","endTime":"0","summary":"北京时间2024年07月26日00时34分，Nuvation Bio Inc.股票出现异动，股价大幅拉升5.26%。截至发稿，该股报3.80美元/股，成交量69.6284万股，换手率0.28%，振幅6.93%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726003449aefb7ae9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726003449aefb7ae9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","BK4231","NUVB","BK4080","DDC","BK4212","BK4007"],"gpt_icon":0},{"id":"2454826887","title":"艾伯维(ABBV.US)创新ADC在华申报临床 用于治疗小细胞肺癌等","url":"https://stock-news.laohu8.com/highlight/detail?id=2454826887","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454826887?lang=zh_cn&edition=full","pubTime":"2024-07-25 18:57","pubTimestamp":1721905032,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月25日，中国国家药监局药品审评中心官网公示，艾伯维申报的ABBV-706注射用冻干粉临床试验申请获得受理。公开资料显示，ABBV-706是一种靶向SEZ6的抗体偶联药物，有效载荷为TOP1i，目前正在国际范围内处于1期临床研究阶段。此次是这款SEZ6靶向ADC在研产品首次在中国申报临床。根据艾伯维官网管线资料，ABBV-706正在针对非小细胞肺癌开展1期临床研究，未来该产品还有望用于治疗小细胞肺癌、中枢神经系统肿瘤和神经内分泌癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ABBV","BK4550","LU0029864427.USD","LU1244550494.USD","LU0545039389.USD","BK4080","LU1267930490.SGD","BK4533","LU0256863902.USD","LU0820561818.USD","LU1244550577.SGD","LU0795875086.SGD","LU1003077747.HKD","LU0211328371.USD","LU0234572021.USD","LU0417517546.SGD","LU1061106388.HKD","BK4585","LU0820561909.HKD","LU0985320562.USD","BK4139","IE00BSNM7G36.USD","BK4588","LU0708994859.HKD","LU1057294990.SGD","BK4566","ADC","LU0882574055.USD","LU0256863811.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0310799852.SGD","LU0158827948.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU0170899867.USD","LU1496350502.SGD","LU1496350171.SGD","LU0949170772.SGD","LU0122379950.USD","LU0234570918.USD","LU0310800379.SGD","BK4581","LU1291159041.SGD","LU1093756325.SGD","LU0114720955.EUR","BK4534","IE0002141913.USD","IE0004445239.USD"],"gpt_icon":0},{"id":"2454498248","title":"博安生物(06955)自主开发的创新ADC候选药物BA1302在中国获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2454498248","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454498248?lang=zh_cn&edition=full","pubTime":"2024-07-25 16:44","pubTimestamp":1721897045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 公布，公司自主开发的创新抗体偶联药物注射用的BA1302已获中华人民共和国国家药品监督管理局药品审评中心批准进行临床试验，用于治疗晚期实体瘤。临床前研究数据显示，BA1302具有优异的内化活性和旁杀作用。BA1302在食蟹猴体内显示出较长的半衰期和良好的药代特征，安全耐受性较好，展现出优异的临床治疗潜力。截至目前，国内尚无同靶点ADC药物进入临床试验阶段。BA1302将是目前全球唯一在临床阶段的靶向CD228的抗体偶联药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK4080","03347","BK1161","BK4231","BK1141","BK1576","BK1583","ADC"],"gpt_icon":0},{"id":"2453188524","title":"Nuvation Bio Inc.盘中异动 早盘急速拉升5.18%报3.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453188524","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453188524?lang=zh_cn&edition=full","pubTime":"2024-07-24 22:28","pubTimestamp":1721831300,"startTime":"0","endTime":"0","summary":"北京时间2024年07月24日22时28分，Nuvation Bio Inc.股票出现异动，股价大幅上涨5.18%。截至发稿，该股报3.45美元/股，成交量42.6076万股，换手率0.17%，振幅6.71%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407242228209681fdca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407242228209681fdca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADC","BK4539","BK4080","NUVB","DDC","BK4139","BK4007","DRMA","BK4212","BK4231"],"gpt_icon":0},{"id":"2453888906","title":"解构“妖股”通化金马","url":"https://stock-news.laohu8.com/highlight/detail?id=2453888906","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453888906?lang=zh_cn&edition=full","pubTime":"2024-07-24 21:47","pubTimestamp":1721828837,"startTime":"0","endTime":"0","summary":"每经记者：林姿辰    每经编辑：杨夏7月2日，美国食品药品监督管理局（FDA）批准Kisunla（Donanemab），礼来制药的阿尔茨海默病疗法用于治疗成人早期症状性阿尔茨海默病（AD）。全球各大药企在阿尔茨海默病新药研发领域折戟早已成为“常态”，美国药物生产与研发协会数据显示，全球累计在AD上的研发投入超过6000亿美元...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OUMbMcj3X396nptZ8ehqWGQjsqa4ohVsoEQlragbqHQxAAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OUMbMcj3X396nptZ8ehqWGQjsqa4ohVsoEQlragbqHQxAAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240724A09WLX00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240724A09WLX00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1576","BK4080","BK4231","BK1583","ADC","BK1141","03347"],"gpt_icon":0},{"id":"2454825207","title":"GAMEON 游戏出海营销峰会如约而至 助力厂商挖掘更多机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2454825207","media":"游戏茶馆","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454825207?lang=zh_cn&edition=full","pubTime":"2024-07-24 18:09","pubTimestamp":1721815740,"startTime":"0","endTime":"0","summary":"7月23日，2024 GAMEON 游戏出海营销峰会如期举办。在本次峰会上，TikTok for Business 展现了其在游戏领域的显著成就和强大影响力。目前，国内小游戏市场竞争激烈，海外市场成为众多游戏厂商寻求增长的新方向。TikTok for Business 指出，将小游戏转为 APP 上线不同地区，能够触达更广泛的玩家群体，挖掘更多增长潜力。游戏出海营销峰会上分享的一个关键要点是，对于新涉足的厂商来说，可以优先考虑以中国台湾作为切入点。2024 年，游戏出海机遇空前，前景广阔。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5OTgzNzkyNA==&mid=2653367005&idx=5&sn=0aefa99f71a282b4b36092cea91be7fa&chksm=bdfce1965c7a58feadc7ef99e2688a85b06b2fb2e174e9c47fb85bc3bdc1b3b6a435ac3398c3&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["ADC","IAA","BK4137","BK4080","LU2098885051.SGD","LU1303367103.USD","BK4231"],"gpt_icon":0},{"id":"2453095852","title":"Agree Realty Corp 公布截至 6 月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2453095852","media":"Reuters","labels":["express"],"top":-1,"share":"https://www.laohu8.com/m/news/2453095852?lang=zh_cn&edition=full","pubTime":"2024-07-24 05:21","pubTimestamp":1721769676,"startTime":"0","endTime":"0","summary":"   * Agree Realty Corp   公布的截至 6 月的季度调整后每股收益为 52 美分，高于去年同期的每股收益 40 美分。七位分析师对该季度的平均预期为每股收益 44 美分。华尔街预期为每股收益 41 美分至 46 美分。* Agree Realty Corp 公布的本季度每股收益为 52 美分。* 公司报告的季度净收入为 5,287 万美元。* Agree Realty Corp 本季度股价上涨了 7.1%，今年迄今为止上涨了 5.3%。7月23日 - 预测变化   * 在过去三个月中，分析师的平均盈利预期上升了约 0.4%。华尔街对 Agree Realty Corp 的 12 个月目标价中位数为 67.25 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"2453717739","title":"Nuvation Bio Inc.盘中异动 临近收盘股价大涨5.00%报3.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453717739","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453717739?lang=zh_cn&edition=full","pubTime":"2024-07-23 03:55","pubTimestamp":1721678103,"startTime":"0","endTime":"0","summary":"北京时间2024年07月23日03时55分，Nuvation Bio Inc.股票出现波动，股价快速上涨5.00%。截至发稿，该股报3.15美元/股，成交量127.663万股，换手率0.51%，振幅4.00%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为1.00%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723035503941f93b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723035503941f93b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4231","BK4212","ADC","BK4080","BK4007","DDC","NUVB"],"gpt_icon":0},{"id":"2453792825","title":"美国研究综述-Align Technology、McKesson、Schneider National","url":"https://stock-news.laohu8.com/highlight/detail?id=2453792825","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453792825?lang=zh_cn&edition=full","pubTime":"2024-07-22 23:31","pubTimestamp":1721662281,"startTime":"0","endTime":"0","summary":"    路透7月22日 - 华尔街证券分析师周一调整了对 Align Technology、McKesson 和 Schneider National 等几家美国上市公司的评级和目标价。* McKesson Corp   ：瑞银将目标价从630美元上调至670美元              * Schneider National   ：美国银行全球研究将其评级从 \"中性 \"下调至 \"跑输大市\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APA","PINE","AN","LU0149725797.USD","ALV","BKU","BCML","AXP","ALX","BHP","AGEN","LU1244550221.USD","BANR","AUGX","BANF","BK4141","PPG","ANF","ARCB","OZK","AEP","AXSM","AMZN","CMA","BHLB","BGS","AA","AES","LU0476273544.USD","BNTC","ACM","AMD","AAL","BMI","AVBP","BE","BRBR","ALGN","BAC","AXL","LU1880398554.USD","LU2242652126.USD","BCBP","TXG","ADC","AGCO","ANAB","LU","AMRC","IE0034235188.USD"],"gpt_icon":0},{"id":"2453755009","title":"强生的ADC版图：前列腺癌能否成为突破口？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453755009","media":"药智网","labels":["Company Corporation","Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453755009?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:06","pubTimestamp":1721635563,"startTime":"0","endTime":"0","summary":"2024年，强生又与ADC生物技术公司Ambrx Biopharma达成收购协议，20亿美元囊获多款临床阶段ADC药物。本次交易，强生看中的是Mersana的二代ADC平台Dolasynthen。目前，强生与多禧生物合作的ADC项目尚未公布研究进展。前列腺癌潜力ADC：ARX517世界癌症研究基金会的数据显示，前列腺癌是全球男性第二大常见的癌症。这个阶段的前列腺癌患者，标准治疗中的放化疗、激素治疗往往可能失效，亟需找到新的有效治疗。Ambrx表示，强生将加速ARX517治疗晚期前列腺癌的I/II期APEX-01研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072216173195e79bb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072216173195e79bb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation,Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0466842654.USD","LU1244550221.USD","BK4568","LU1221951046.USD","LU1066053197.SGD","BK4007","SG9999001440.SGD","LU0795875169.SGD","LU1162221912.USD","BK4550","LU1244550494.USD","LU1196500208.SGD","BK4588","LU1066051225.USD","LU0114720955.EUR","LU2133065610.SGD","LU1032955483.USD","BK4585","LU1935042991.SGD","JNJ","BK4581","LU1732799900.SGD","BK4559","IE00BSNM7G36.USD","LU2602419157.SGD","LU1066051498.USD","LU1221951129.SGD","LU1059921491.USD","IE000M9KFDE8.USD","BK4504","ADC","LU0882574055.USD","LU0122379950.USD","LU0234572021.USD","LU1032466523.USD","LU0345770993.USD","LU1929549753.HKD","BK4592","IE00B19Z3581.USD","LU0889566641.SGD","LU0795875086.SGD","SG9999002224.SGD","BK4231","LU0640476718.USD","LU2347655156.SGD","LU1506573853.SGD","LU1430594728.SGD","LU1074936037.SGD","LU0345770308.USD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2452843082","title":"Agree Realty Corp   预计每股收益44美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2452843082","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452843082?lang=zh_cn&edition=full","pubTime":"2024-07-20 05:45","pubTimestamp":1721425516,"startTime":"0","endTime":"0","summary":"   * Agree Realty Corp    将于7月23日公布截至2024年6月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，13位分析师的平均预期显示，这家总部位于密歇根州皇家橡树市的公司的营收将从去年同期的1.299亿美元增至1.47854亿美元，增幅为13.8%。* LSEG 分析师对 Agree Realty Corp 的平均预期为每股收益 44 美分。* 华尔街对 Agree Realty Corp 的 12 个月目标价中位数为 67.00 美元，高于其上次收盘价 66.68 美元。7月19日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"gpt_icon":0},{"id":"2452402917","title":"Nuvation Bio Inc.盘中异动 下午盘快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452402917","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452402917?lang=zh_cn&edition=full","pubTime":"2024-07-20 02:20","pubTimestamp":1721413237,"startTime":"0","endTime":"0","summary":"北京时间2024年07月20日02时20分，Nuvation Bio Inc.股票出现波动，股价大幅跳水5.03%。截至发稿，该股报3.02美元/股，成交量85.2686万股，换手率0.34%，振幅6.29%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240720022038aefa8d44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240720022038aefa8d44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","BK4080","NUVB","BK4212","BK4231","ADC","BK4007","VRPX"],"gpt_icon":0},{"id":"2452436737","title":"Nuvation Bio Inc.盘中异动 临近午盘大幅下挫5.01%报3.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452436737","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452436737?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:48","pubTimestamp":1721317727,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日23时48分，Nuvation Bio Inc.股票出现异动，股价急速跳水5.01%。截至发稿，该股报3.22美元/股，成交量27.675万股，换手率0.11%，振幅4.87%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为1.93%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407182348489681e1d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407182348489681e1d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","NUVB","BK4212","ADC","BK4007","DDC","BK4231"],"gpt_icon":0},{"id":"2452356185","title":"港股异动 | 科伦博泰生物-B(06990)再涨超5% 解禁后股价连续反弹 机构指其ADC领域研发实力强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2452356185","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452356185?lang=zh_cn&edition=full","pubTime":"2024-07-17 15:00","pubTimestamp":1721199608,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B午后再涨超5%，截至发稿，涨4.88%，报157港元，成交额1.06亿港元。7月11至今，该股累计涨幅已超18%。消息面上，科伦博泰生物上市届满一年，7月12日迎来超1亿股H股解禁。以上ADC产品临床试验的顺利推进均再次印证公司在ADC领域的强劲研发实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","YANG","HSCEI","BK4080","LU0196878994.USD","06990","BK4231","ADC","BK1161"],"gpt_icon":1},{"id":"2452077669","title":"【港股通】科伦博泰生物(06990)涨3.74% 机构指其ADC研发实力强 有望受益于创新药政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452077669","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452077669?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:58","pubTimestamp":1721195923,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦博泰生物 股价走高，截止发稿，涨3.74%，报155.3港元，成交额7606.15万港元。以上ADC产品临床试验的顺利推进均再次印证公司在ADC领域的强劲研发实力。首次覆盖，给予“买入”评级。东吴证券表示，《全链条支持创新药发展实施方案》具体条款有望近期落地，叠加创新药板块处于历史相对底部位置，下半年有ESMO大会、WCLC大会、医保谈判、创新药出海预期等多重催化，创新药板块有望走强。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940551","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","BK4231","06990","HSCEI","BK1161","HSTECH","BK4080","06978","ADC","BK1574","LU0196878994.USD","159992"],"gpt_icon":1},{"id":"2451590750","title":"20cm闪崩跌停，“ADC药物第一股”急了，当日召集150家机构开会，通报三大“内情”！多家千亿巨头被机构盯上","url":"https://stock-news.laohu8.com/highlight/detail?id=2451590750","media":"数据宝","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451590750?lang=zh_cn&edition=full","pubTime":"2024-07-13 12:01","pubTimestamp":1720843260,"startTime":"0","endTime":"0","summary":"近期，恒生电子发布的业绩预告显示，上半年净利3537.7万元，同比下降92.07%。7月9日，荣昌生物股价20cm跌停，周一至周三累计跌幅达到35%，股价在本周创出历史新低。在周三暴跌当日，荣昌生物火速举行电话会议，向市场通报包括RC18国际合作进展、现金流情况以及海外专利到期等问题。当日参与会议的有150家机构。本周A股各主要指数集体反弹，上证指数周涨幅达0.72%，创业板指更是大涨1.69%。梳理发现，近一周机构调研股平均上涨1.85%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4MDU0MzQ4Mg==&mid=2653365188&idx=1&sn=75596291db539c000efd8e4eabdf0921&chksm=85b2c1b357cf605157746120c0766a02455ea92494f0d1c39547f4237525e78c1f7373811951&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2450366191","title":"Nuvation Bio Inc.盘中异动 急速拉升5.00%报3.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450366191","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450366191?lang=zh_cn&edition=full","pubTime":"2024-07-11 22:18","pubTimestamp":1720707497,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日22时18分，Nuvation Bio Inc.股票出现波动，股价大幅上涨5.00%。截至发稿，该股报3.36美元/股，成交量16.72万股，换手率0.07%，振幅3.84%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.87%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711221817af91df6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711221817af91df6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","ADC","BK4007","BK4212","BK4080","NUVB","BK4231"],"gpt_icon":0},{"id":"2450436615","title":"协和医院教授研发的一款ADC药物卖了10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450436615","media":"经济观察报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450436615?lang=zh_cn&edition=full","pubTime":"2024-07-11 21:49","pubTimestamp":1720705746,"startTime":"0","endTime":"0","summary":"经济观察网 记者 张铃7月11日，昱言科技宣布与法国药企益普生就药物分子FS001达成合作：昱言科技将FS001在全球范围内开发、制造和商业化的独家权利许可给益普生，潜在总交易额为10.3亿美元。具体而言，FS001是一款具有首创新药（First-in-class）潜力的抗体偶联药物 （ADC），10.3亿美元包括首付款、开发、监管和商业化重要...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OQeHQylldnhKbSfs5f5nisVmL4XZr0gUguwmW9IMYPBrIAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OQeHQylldnhKbSfs5f5nisVmL4XZr0gUguwmW9IMYPBrIAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240711A09R8F00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240711A09R8F00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2450337763","title":"百利天恒(688506.SH)：注射用BL-M14D1(ADC)项目治疗晚期实体瘤获批I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2450337763","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450337763?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:45","pubTimestamp":1720694733,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M14D1(ADC)的药物临床试验获得批准。BL-M14D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4023","BK1141","03347","BK4231","BK0239","BL","688506","BK4080","LU0757428866.USD","ADC","LU1815336091.USD","BK1576"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0.0212},{"period":"1month","weight":0.1162},{"period":"3month","weight":0.1754},{"period":"6month","weight":0.1418},{"period":"1year","weight":-0.0169},{"period":"ytd","weight":0.0786}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":-0.004913},{"month":2,"riseRate":0.433333,"avgChangeRate":-0.00204},{"month":3,"riseRate":0.566667,"avgChangeRate":0.014268},{"month":4,"riseRate":0.566667,"avgChangeRate":0.002707},{"month":5,"riseRate":0.516129,"avgChangeRate":0.017098},{"month":6,"riseRate":0.677419,"avgChangeRate":0.011409},{"month":7,"riseRate":0.677419,"avgChangeRate":0.023625},{"month":8,"riseRate":0.433333,"avgChangeRate":-0.000088},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.007022},{"month":10,"riseRate":0.566667,"avgChangeRate":-0.000808},{"month":11,"riseRate":0.633333,"avgChangeRate":0.001669},{"month":12,"riseRate":0.5,"avgChangeRate":0.014772}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}